Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the immunisation protects at-risk babies

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”

The pregnancy vaccine operates by activating the mother’s immune system to generate protective antibodies, which are then transferred to the developing baby through the placenta. This maternal immunity offers newborns with immediate protection from the moment of birth, exactly when they are highly susceptible to RSV. The latest research demonstrates that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence indicating that a two-week gap is adequate to shield babies born slightly early. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst noting that protection remains possible even if administered later in the third trimester.

• Nearly 85% protection when vaccinated 4 weeks before birth
• Maternal antibodies transferred through placenta protect newborns from birth
• Protection possible with 2-week gap before premature birth
• Vaccination in the third trimester still offers meaningful infant protection

Compelling evidence from the latest research

The efficacy of the pregnancy RSV vaccine has been demonstrated through a comprehensive study undertaken in England, reviewing data from close to 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90 per cent of all births during that half-year window, providing comprehensive and reliable information of the vaccine’s real-world impact. The study’s conclusions have been supported by the UK Health Security Agency as showing strong protection for newborns during their most critical early weeks. The scope of this study offers healthcare professionals and parents-to-be with trust in the vaccine’s demonstrated effectiveness across different groups and contexts.

The results paint a striking picture of the vaccine’s protective effectiveness. More than 4,500 babies were hospitalised with RSV throughout the study period, with the vast majority being infants whose mothers did not receive the vaccination. This clear distinction underscores the vaccine’s vital importance in protecting against serious illness in newborns. The decrease in hospital admissions exceeding 80 per cent represents a substantial public health milestone, potentially preventing thousands of infants from experiencing the alarming and potentially severe symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme introduced in the UK in 2024.

Methodology and scope of study

The research analysed birth and hospital admission records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection levels and hospital admissions. The sizeable sample and comprehensive nature of the data collection ensured that findings were statistically robust and indicative of the general population, rather than individual cases or small subgroups.

The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at different timepoints before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with reduced timeperiods. The methodology captured actual clinical results rather than laboratory-based settings, providing practical evidence of how the vaccine works when administered across diverse clinical settings and patient circumstances throughout the third trimester of pregnancy.

Understanding RSV and its threats

Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity changing substantially from mild cold-like symptoms to severe, life-threatening chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during busier periods.

The infection produces inflammation deep within the lungs and airways, making it extremely challenging for affected infants to feed and breathe adequately. Parents frequently observe their babies visibly struggling, their chests rising whilst they attempt to draw sufficient oxygen into their compromised lungs. Whilst most infants recover with palliative treatment, a modest yet notable proportion perish from RSV-related complications each year, making immunisation programmes a essential public health priority for protecting the youngest and most at-risk individuals in the population.

• RSV triggers inflammation in lungs, leading to severe breathing difficulties in infants
• Nearly 50% of infants catch the infection in their first few months of life
• Symptoms span from minor cold-like symptoms to serious chest infections that threaten life needing hospital treatment
• Over 20,000 UK infants need serious hospital treatment for RSV annually
• A small number of babies succumb to RSV complications each year in the UK

Take-up rates and expert recommendations

Since the RSV vaccine programme launched in 2024, health officials have emphasised the importance of pregnant women getting their jab at the optimal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that the timing is essential for guaranteeing newborns benefit from the most robust immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery delivers approximately 85% protection, experts recommend women to get their vaccine as soon as feasible from 28 weeks of pregnancy onwards to maximise the antibodies transferred to their babies via the placenta.

The messaging from public health bodies remains clear: pregnant women ought to prioritise getting vaccinated during their final three months, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has reassured expectant mothers that protection remains still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those delivering slightly early. This adaptable strategy acknowledges the practical demands of pregnancy whilst maintaining strong safeguarding for vulnerable newborns during their earliest and most vulnerable period when RSV represents the highest danger of severe infection.

Regional disparities in vaccination

Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have varied across various areas and NHS trusts. Some areas have attained higher vaccination coverage among eligible pregnant women, whilst others remain focused to boost understanding and access to the jab. These regional differences demonstrate variations in medical facilities, engagement approaches, and community involvement initiatives, though the overall statistics demonstrates robust and reliable protection regardless of geographical location.

• NHS trusts launching varied communication campaigns to reach women during pregnancy
• Geographic variations in immunisation take-up throughout England demand focused enhancement
• Local healthcare systems tailoring initiatives to align with local requirements and situations

Practical implications and parent viewpoints

The vaccine’s remarkable effectiveness translates into tangible benefits for families across the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV before the rollout of this protective measure, the 80% decrease in admissions represents thousands of infants shielded from critical disease. Parents no more face the troubling prospect of seeing their babies gasping for air or difficulty feeding, symptoms that mark critical RSV illness. The vaccine has substantially transformed the landscape of neonatal respiratory health, offering expectant mothers a proactive tool to safeguard their most at-risk babies during those critical early months.

For families like that of Malachi, whose severe RSV infection led to devastating brain damage, the vaccine’s availability carries significant emotional significance. His mother’s advocacy for the jab underscores the profound consequences that preventable illness can inflict on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story strikes a chord with parents now provided with protection. The knowledge that such grave complications—hospital stay, oxygen dependency, neurological damage—are now mostly preventable has offered substantial reassurance to expectant mothers navigating their third trimester, converting what was once an inevitable seasonal threat into a controllable health concern.